MedTrace Logo

A Study of Lianxiaxiaopi Granules in the Treatment of Postprandial Distress Syndrome

NCT06696261 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 342

Last updated 2026-01-20

No results posted yet for this study

Summary

The goal of this clinical trial is evaluating the efficacy and safety of Lianxiaxiaopi Granules in participant population. The main questions it aims to answer are:

1. Based on the Response rate of postprandial distress syndrome participants, evaluate whether the efficacy of Lianxiaxiaopi Granules is superior to placebo.
2. Evaluate the efficacy of Lianxiaxiaopi Granules in improving symptom of postprandial distress syndrome.
3. Evaluating the safety of Lianxiaxiaopi Granules in postprandial distress syndrome participants.

Conditions

  • Postprandial Distress Syndrome

Interventions

DRUG

Lianxiaxiaopi Granules

The participants took orally 1 sachet of Lianxiaxiaopi Granules, 3 times a day for 8 weeks.

DRUG

a simulated agent of Lianxiaxiaopi Granules

The participants took orally 1 sachet of simulated agent of Lianxiaxiaopi Granules, 3 times a day for 8 weeks.

Sponsors & Collaborators

  • Tasly Pharmaceutical Group Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-27
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06696261 on ClinicalTrials.gov